The DOI matches its Crossref record; 88 of the 88 references it cites were found in a registry or an index.
The Intriguing History of Cancer Immunotherapy
Open accessAbstract
Immunotherapy is often perceived as a relatively recent advance. In reality, however, one should be looking for the beginnings of cancer immunotherapy under different names as far as in the Antiquity. The first scientific attempts to modulate patients' immune systems to cure cancer can be attributed to two German physicians, Fehleisen and Busch, who independently noticed significant tumor regression after erysipelas infection. The next significant advances came from William Bradley Coley who is known today as the Father of Immunotherapy. It was Coley who first attempted to harness the immune system for treating bone cancer in 1891. His achievements were largely unnoticed for over fifty years, and several seminal discoveries in the field of Immunology, such as the existence of T cells and their crucial role in immunity in 1967, stepped up the research toward cancer immunotherapy known today. The following paper tracks cancer immunotherapy from its known beginnings up until recent events, including the 2018 Nobel Prize award to James Allison and Tasuku Honjo for their meticulous work on checkpoint molecules as potential therapeutic targets. That work has led to the successful development of new checkpoint inhibitors, CAR T-cells and oncolytic viruses and the pace of such advances brings the highest hope for the future of cancer treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474 · cited 1×
“Further discoveries followed including mechanisms for immunoediting, evidence for cancer cell escape and the recognition that immunosuppressed patients have significantly higher risk of cancer development (4, 31, 33).”
BackgroundPark, J.-H., Adoro, S., Guinter, T., Erman, B., Alag, A. S., Catalfamo, M., Kimura, M. Y., Cui, Y., Lucas, P. J., Gress, R. E., et al. (2010) · Nature Immunology · doi:10.1038/ni.1840 · Cited by 5,835
Sakaguchi, S., Sakaguchi, N., Asano, M., Itoh, M., & Toda, M. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.155.3.1151 · Cited by 5,608 · cited 2×
“Furthermore, increased incidence of cancer is observed in immunosuppressed patients, what at least partially had been attributed to the actions of Tregs in 1995 (57, 68).”
BackgroundPrimary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.017 · Cited by 5,588
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
Kantoff, P. W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. J., Penson, D. F., Redfern, C. H., Ferrari, A. C., Dreicer, R., Sims, R. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001294 · Cited by 5,572 · cited 2×
“This dendritic, cell-based vaccine appeared to extend overall survival of patients during the clinical trials but unfortunately in the clinical setting had no effect on disease progression (6, 75).”
BackgroundCancer immunoediting: from immunosurveillance to tumor escape
Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J., & Schreiber, R. D. (2002) · Nature Immunology · doi:10.1038/ni1102-991 · Cited by 5,393
Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients
Gopalakrishnan, V., Spencer, C. N., Nezi, L., Reuben, A., Andrews, M. C., Karpinets, T. V., Prieto, P. A., Vicente, D., Hoffman, K., Wei, S. C., et al. (2018) · Science · doi:10.1126/science.aan4236 · Cited by 4,812
Enhancement of Antitumor Immunity by CTLA-4 Blockade
Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955
A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma
van der Bruggen, P., Traversari, C., Chomez, P., Lurquin, C., De Plaen, E., Van den Eynde, B., Knuth, A., & Boon, T. (1991) · Science · doi:10.1126/science.1840703 · Cited by 3,545
Virus interference. I. the interferon
Isaacs, A., & Lindenmann, J. (1957) · Proceedings of the Royal Society of London. Series B - Biological Sciences · doi:10.1098/rspb.1957.0048 · Cited by 3,451
The Three Es of Cancer Immunoediting
Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104803 · Cited by 3,072
IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity
Shankaran, V., Ikeda, H., Bruce, A. T., White, J. M., Swanson, P. E., Old, L. J., & Schreiber, R. D. (2001) · Nature · doi:10.1038/35074122 · Cited by 2,896
Rosenberg, S. A., Lotze, M. T., Muul, L. M., Leitman, S., Chang, A. E., Ettinghausen, S. E., Matory, Y. L., Skibber, J. M., Shiloni, E., Vetto, J. T., et al. (1985) · New England Journal of Medicine · doi:10.1056/nejm198512053132327 · Cited by 2,653
Selective in Vitro Growth of T Lymphocytes from Normal Human Bone Marrows
Morgan, D. A., Ruscetti, F. W., & Gallo, R. (1976) · Science · doi:10.1126/science.181845 · Cited by 2,493
IDENTIFICATION OF A NOVEL CELL TYPE IN PERIPHERAL LYMPHOID ORGANS OF MICE
Steinman, R. M., & Cohn, Z. A. (1973) · The Journal of Experimental Medicine · doi:10.1084/jem.137.5.1142 · Cited by 2,424
Rosenberg, S. A., Packard, B. S., Aebersold, P. M., Solomon, D., Topalian, S. L., Toy, S. T., Simon, P., Lotze, M. T., Yang, J. C., Seipp, C. A., et al. (1988) · New England Journal of Medicine · doi:10.1056/nejm198812223192527 · Cited by 2,389 · cited 1×
“The US FDA approved the use of interleukin 2 as an immunotherapeutic treatment in 1991 for the treatment of metastatic kidney cancer and in 1998 for metastatic melanoma (6, 56).”
BackgroundCD28 and CTLA-4 have opposing effects on the response of T cells to stimulation.
Krummel, M. F., & Allison, J. P. (1995) · The Journal of experimental medicine · doi:10.1084/jem.182.2.459 · Cited by 2,245 · cited 1×
“pinpointed it as a crucial immune checkpoint molecule with great potential as a future anti-cancer therapy target (46, 47).”
BackgroundImmunosuppressive networks in the tumour environment and their therapeutic relevance
Zou, W. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1586 · Cited by 2,057
Inhibitory effect of tumor cell-derived lactic acid on human T cells
Fischer, K., Hoffmann, P., Voelkl, S., Meidenbauer, N., Ammer, J., Edinger, M., Gottfried, E., Schwarz, S., Rothe, G., Hoves, S., et al. (2007) · Blood · doi:10.1182/blood-2006-07-035972 · Cited by 1,946
Kiessling, R., Klein, E., & Wigzell, H. (1975) · European Journal of Immunology · doi:10.1002/eji.1830050208 · Cited by 1,824
Intracavitary Bacillus Calmette-guerin in the Treatment of Superficial Bladder Tumors
Morales, A., Eidinger, D., & Bruce, A. W. (1976) · Journal of Urology · doi:10.1016/s0022-5347(17)58737-6 · Cited by 1,791
Eshhar, Z., Waks, T., Gross, G., & Schindler, D. G. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.2.720 · Cited by 1,658
The Concept of Immunological Surveillance
Burnet, F. M. (2015) · Progress in Tumor Research · doi:10.1159/000386035 · Cited by 1,656
Gross, G., Waks, T., & Eshhar, Z. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.24.10024 · Cited by 1,590
Intracavitary Bacillus Calmette-Guerin in the Treatment of Superficial Bladder Tumors
Morales, A., Eidinger, D., & Bruce, A. W. (2017) · Journal of Urology · doi:10.1016/j.juro.2016.10.101 · Cited by 1,533
The Influence of the Gut Microbiome on Cancer, Immunity, and Cancer Immunotherapy
Gopalakrishnan, V., Helmink, B. A., Spencer, C. N., Reuben, A., & Wargo, J. A. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.015 · Cited by 1,392 · cited 2×
“Several preliminary trials of fecal microbiota transplantations (FMT) have been already conducted with promising results (101, 102).”
BackgroundA new member of the immunoglobulin superfamily—CTLA-4
Brunet, J.-F., Denizot, F., Luciani, M.-F., Roux-Dosseto, M., Suzan, M., Mattei, M.-G., & Golstein, P. (1987) · Nature · doi:10.1038/328267a0 · Cited by 1,306
IL-2: The First Effective Immunotherapy for Human Cancer
Rosenberg, S. A. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1490019 · Cited by 1,289
Structure and expression of a cloned cDNA for human interleukin-2
Taniguchi, T., Matsui, H., Fujita, T., Takaoka, C., Kashima, N., Yoshimoto, R., & Hamuro, J. (1983) · Nature · doi:10.1038/302305a0 · Cited by 1,182
Natural Killer Cells: Development, Maturation, and Clinical Utilization
Abel, A. M., Yang, C., Thakar, M. S., & Malarkannan, S. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01869 · Cited by 1,150
Kiessling, R., Klein, E., Pross, H., & Wigzell, H. (1975) · European Journal of Immunology · doi:10.1002/eji.1830050209 · Cited by 1,143
Intracavitary bacillus Calmette-Grerin in the treatement of superficial bladder tumors
Morales, A. (1976) · The Journal of Urology · Cited by 978
Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors
Melero, I., Shuford, W. W., Newby, S. A., Aruffo, A., Ledbetter, J. A., Hellström, K. E., Mittler, R. S., & Chen, L. (1997) · Nature Medicine · doi:10.1038/nm0697-682 · Cited by 898
The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas.
McCarthy, E. F. (2006) · Europe PMC (PubMed Central) · Cited by 747
Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis
Wang, Y., Wiesnoski, D. H., Helmink, B. A., Gopalakrishnan, V., Choi, K., DuPont, H. L., Jiang, Z.-D., Abu-Sbeih, H., Sanchez, C. A., Chang, C.-C., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0238-9 · Cited by 740 · cited 1×
“Several preliminary trials of fecal microbiota transplantations (FMT) have been already conducted with promising results (101, 102).”
BackgroundFerrara, R., Mezquita, L., Texier, M., Lahmar, J., Audigier-Valette, C., Tessonnier, L., Mazieres, J., Zalcman, G., Brosseau, S., Le Moulec, S., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.3676 · Cited by 720
Neoantigen vaccine: an emerging tumor immunotherapy
Peng, M., Mo, Y., Wang, Y., Wu, P., Zhang, Y., Xiong, F., Guo, C., Wu, X., Li, Y., Li, X., et al. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1055-6 · Cited by 700
Isaacs, A., & Lindenmann, J. (2015) · The Journal of Immunology · doi:10.1093/jimmunol/195.5.1911 · Cited by 602
Biological Activity of Recombinant Human Interleukin-2 Produced in Escherichia coli
Rosenberg, S. A., Grimm, E. A., McGrogan, M., Doyle, M., Kawasaki, E., Koths, K., & Mark, D. F. (1984) · Science · doi:10.1126/science.6367046 · Cited by 595
The urgent need to recover MHC class I in cancers for effective immunotherapy
Garrido, F., Aptsiauri, N., Doorduijn, E. M., Garcia Lora, A. M., & van Hall, T. (2016) · Current Opinion in Immunology · doi:10.1016/j.coi.2015.12.007 · Cited by 585
Xu, J., Escamilla, J., Mok, S., David, J., Priceman, S., West, B., Bollag, G., McBride, W., & Wu, L. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3981 · Cited by 569
Tumor-specific antigen of murine T-lymphoma defined with monoclonal antibody.
Allison, J. P., McIntyre, B. W., & Bloch, D. (1982) · The Journal of Immunology · doi:10.4049/jimmunol.129.5.2293 · Cited by 541
Effect of Bacillus Calmette-Guérin Infection on Transplanted Tumours in the Mouse
OLD, L. J., CLARKE, D. A., & BENACERRAF, B. (1959) · Nature · doi:10.1038/184291a0 · Cited by 539
Steinbrink, K., Graulich, E., Kubsch, S., Knop, J., & Enk, A. H. (2002) · Blood · doi:10.1182/blood.v99.7.2468 · Cited by 448
Paul Ehrlich (1854-1915) and His Contributions to the Foundation and Birth of Translational Medicine
Valent, P., Groner, B., Schumacher, U., Superti-Furga, G., Busslinger, M., Kralovics, R., Zielinski, C., Penninger, J. M., Kerjaschki, D., Stingl, G., et al. (2016) · Journal of Innate Immunity · doi:10.1159/000443526 · Cited by 409
Tumor neoantigens: from basic research to clinical applications
Jiang, T., Shi, T., Zhang, H., Hu, J., Song, Y., Wei, J., Ren, S., & Zhou, C. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0787-5 · Cited by 386
The onset and extent of genomic instability in sporadic colorectal tumor progression
Stoler, D. L., Chen, N., Basik, M., Kahlenberg, M. S., Rodriguez-Bigas, M. A., Petrelli, N. J., & Anderson, G. R. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.26.15121 · Cited by 383
Tumor-Associated Macrophages: The Double-Edged Sword in Cancer Progression
Chen, J. J. W., Lin, Y.-C., Yao, P.-L., Yuan, A., Chen, H.-Y., Shun, C.-T., Tsai, M.-F., Chen, C.-H., & Yang, P.-C. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.12.172 · Cited by 374
Cancer immunotherapy: a brief review of the history, possibilities, and challenges ahead
Oiseth, S. J., & Aziz, M. S. (2017) · Journal of Cancer Metastasis and Treatment · doi:10.20517/2394-4722.2017.41 · Cited by 369
Tumor Development after 3-Methylcholanthrene in Immunologically Deficient Athymic-Nude Mice
Stutman, O. (1974) · Science · doi:10.1126/science.183.4124.534 · Cited by 356
The Immune Revolution: A Case for Priming, Not Checkpoint
Vonderheide, R. H. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.008 · Cited by 293
Garrido, F., Cabrera, T., & Aptsiauri, N. (2010) · International Journal of Cancer · doi:10.1002/ijc.25270 · Cited by 276
Decker, W. K., da Silva, R. F., Sanabria, M. H., Angelo, L. S., Guimarães, F., Burt, B. M., Kheradmand, F., & Paust, S. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00829 · Cited by 246
Cytotoxic lymphocytes from normal donors. A functional marker of human non-T lymphocytes.
Pross, H. F., & Jondal, M. (1975) · PubMed · Cited by 229
Cancer immunotherapy targeting neoantigens
Lu, Y.-C., & Robbins, P. F. (2016) · Seminars in Immunology · doi:10.1016/j.smim.2015.11.002 · Cited by 223
LOMBARD, M., PASTORET, P.-P., & MOULIN, A. M. (2007) · Revue Scientifique et Technique de l'OIE · doi:10.20506/rst.26.1.1724 · Cited by 212
Kappler, J., Kubo, R., Haskins, K., Hannum, C., Marrack, P., Pigeon, M., McIntyre, B., Allison, J., & Trowbridge, I. (1983) · Cell · doi:10.1016/0092-8674(83)90232-5 · Cited by 205
Looi, C.-K., Chung, F. F.-L., Leong, C.-O., Wong, S.-F., Rosli, R., & Mai, C.-W. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1153-8 · Cited by 202
de Gruijl, T. D., van den Eertwegh, A. J. M., Pinedo, H. M., & Scheper, R. J. (2008) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-008-0536-z · Cited by 201
Tolerance to apoptotic cells is regulated by indoleamine 2,3-dioxygenase
Ravishankar, B., Liu, H., Shinde, R., Chandler, P., Baban, B., Tanaka, M., Munn, D. H., Mellor, A. L., Karlsson, M. C. I., & McGaha, T. L. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1117736109 · Cited by 198
Herbst, R. S., Gordon, M. S., Fine, G. D., Sosman, J. A., Soria, J.-C., Hamid, O., Powderly, J. D., Burris, H. A., Mokatrin, A., Kowanetz, M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.3000 · Cited by 190
Role of the immunosuppressive microenvironment in immunotherapy
Tormoen, G. W., Crittenden, M. R., & Gough, M. J. (2018) · Advances in Radiation Oncology · doi:10.1016/j.adro.2018.08.018 · Cited by 189
Immunotherapy of Cancer with 4-1BB
Vinay, D. S., & Kwon, B. S. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0677 · Cited by 180
Volcheck, G. W. (2001) · Annals of Allergy, Asthma & Immunology · doi:10.1016/s1081-1206(10)63314-5 · Cited by 179
4-1BB (CD137), an inducible costimulatory receptor, as a specific target for cancer therapy
Vinay, D. S., & Kwon, B. S. (2014) · BMB Reports · doi:10.5483/bmbrep.2014.47.3.283 · Cited by 165
Sharma, A., Koldovsky, U., Xu, S., Mick, R., Roses, R., Fitzpatrick, E., Weinstein, S., Nisenbaum, H., Levine, B. L., Fox, K., et al. (2012) · Cancer · doi:10.1002/cncr.26734 · Cited by 164
Paul Ehrlich — in search of the magic bullet
Winau, F., Westphal, O., & Winau, R. (2004) · Microbes and Infection · doi:10.1016/j.micinf.2004.04.003 · Cited by 164
Cellular Basis of the Immunological Defects in Thymectomized Mice
Miller, J. F. A. P., Mitchell, G. F., & WEISS, N. S. (1967) · Nature · doi:10.1038/214992a0 · Cited by 155
Going viral: a review of replication-selective oncolytic adenoviruses
Larson, C., Oronsky, B. T., Scicinski, J. J., Fanger, G. R., Stirn, M., Oronsky, A. L., & Reid, T. R. (2015) · Oncotarget · doi:10.18632/oncotarget.5116 · Cited by 140
Direct reprogramming of fibroblasts into antigen-presenting dendritic cells
Rosa, F. A., Pires, C. F., Kurochkin, I., Ferreira, A. G., Gomes, A., Palma, L. G., Shaiv, K., Solanas, L., Azenha, C. D. J., Papatsenko, D. A., et al. (2018) · Science Immunology · doi:10.1126/sciimmunol.aau4292 · Cited by 132
Mutation-Derived Neoantigens for Cancer Immunotherapy
Castle, J. C., Uduman, M., Pabla, S. S., Stein, R. B., & Buell, J. S. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01856 · Cited by 129
Avigan, D., Vasir, B., George, D. J., Oh, W. K., Atkins, M. B., McDermott, D. F., Kantoff, P. W., Figlin, R. A., Vasconcelles, M. J., Xu, Y., et al. (2007) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3180de4ce8 · Cited by 123
The T-Body Approach: Redirecting T Cells with Antibody Specificity
Eshhar, Z. (2007) · Handbook of experimental pharmacology · doi:10.1007/978-3-540-73259-4_14 · Cited by 111
Mollanoori, H., Shahraki, H., Rahmati, Y., & Teimourian, S. (2018) · Human Immunology · doi:10.1016/j.humimm.2018.09.007 · Cited by 109
An Update on Immunotherapy for Solid Tumors: A Review
Pham, T. D., Roth, S., Kong, J. C. H., Guerra, G., Narasimhan, V., Pereira, L. A., Desai, J., Heriot, A. G., & Ramsay, R. G. (2018) · Annals of Surgical Oncology · doi:10.1245/s10434-018-6658-4 · Cited by 108
Rudnicka, D., Oszmiana, A., Finch, D. K., Strickland, I., Schofield, D. J., Lowe, D. C., Sleeman, M. A., & Davis, D. M. (2013) · Blood · doi:10.1182/blood-2013-02-482570 · Cited by 107
Stutman, O. (1979) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/62.2.353 · Cited by 106
Bioimmunoadjuvants for the treatment of neoplastic and infectious disease: Coley's legacy revisited
Decker, W. K., & Safdar, A. (2009) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2009.07.004 · Cited by 101
The hybridoma revolution: an offshoot of basic research
Milstein, C. (1999) · BioEssays · doi:10.1002/(sici)1521-1878(199911)21:11<966::aid-bies9>3.0.co;2-z · Cited by 97
Powles, T. B., Vogelzang, N. J., Fine, G. D., Eder, J. P., Braiteh, F. S., Loriot, Y., Cruz, C., Joaquim Bellmunt, B., Burris, H. A., Teng, S.-L. M., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.5011 · Cited by 96
CRISPR/Cas9-based genome editing in the era of CAR T cell immunotherapy
Salas-McKee, J., Kong, W., Gladney, W. L., Jadlowsky, J. K., Plesa, G., Suhoski, M. M., & Fraietta, J. A. (2019) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2019.1571893 · Cited by 68
Old, L. J. (1977) · Scientific American · doi:10.1038/scientificamerican0577-62 · Cited by 56
Targeting Legumain As a Novel Therapeutic Strategy in Cancers
Mai, C., Chung, F. F., & Leong, C.-O. (2017) · Current Drug Targets · doi:10.2174/1389450117666161216125344 · Cited by 52
Targeting immunosuppression for cancer therapy
Ghirelli, C., & Hagemann, T. (2013) · Journal of Clinical Investigation · doi:10.1172/jci69999 · Cited by 49
Immunosuppressants in cancer prevention and therapy
Blagosklonny, M. V. (2013) · OncoImmunology · doi:10.4161/onci.26961 · Cited by 48
Nocera, N. F., Lee, M. C., Cruz, L. M. D. L., Rosemblit, C., & Czerniecki, B. J. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00356 · Cited by 42
Personalized tumor vaccines keep cancer in check
Kaiser, J. (2017) · Science · doi:10.1126/science.356.6334.122 · Cited by 28
Cited by
Therapeutic cancer vaccines: Advancements, challenges, and prospects
Fan, T., Zhang, M., Yang, J., Zhu, Z., Cao, W., & Dong, C. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01674-3 · Cited by 597
“162 Currently, using bacteria as carriers to deliver tumor antigens has many advantages.”
BackgroundFrom bench to bedside: the history and progress of CAR T cell therapy
Mitra, A., Barua, A., Huang, L., Ganguly, S., Feng, Q., & He, B. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1188049 · Cited by 466
Colorectal Cancer Immunotherapy: Options and Strategies
Johdi, N. A., & Sukor, N. F. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01624 · Cited by 452
A comprehensive review of immune checkpoint inhibitors for cancer treatment
Arafat Hossain, M. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113365 · Cited by 178
Assessing the future of solid tumor immunotherapy
Guha, P., Heatherton, K. R., O’Connell, K. P., Alexander, I. S., & Katz, S. C. (2022) · Biomedicines · doi:10.3390/biomedicines10030655 · Cited by 105
Metadata
- Authors
- Dobosz, P., & Dzieciątkowski, T.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2019-12-17
- Volume
- 10
- Pages
- 2965-2965
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W2996316560
- Cited by
- 458
- References
- 88
- FWCI
- 14.42
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.